ImmuneID
Latest round
- Series A
Last raised
- Apr 2021
Total raised
- $59M
Investors
- 10
About ImmuneID
Founded in 2020 and based in Massachusetts, US, ImmuneID, Inc. operates as a precision immunology company that developed a medical proprietary platform to identify antibody interactions for infectious diseases. The company was co-founded by Christoph Westphal and Lea Hachigian. ImmuneID, Inc. The company offers a comprehensive understanding of individual immune responses to employ massively parallel, multiplexed, and unbiased systems to identify therapeutically target millions of antibody interactions for severe allergy, oncology, and infectious disease. In February 2021, the company plans to develop therapeutic programs in areas including severe allergy, autoimmunity, oncology, and infectious disease.
Who invested in ImmuneID
10 investors across 2 rounds
See all investors in ImmuneID
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ImmuneID
Who invested in ImmuneID?
ImmuneID has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ImmuneID raised?
ImmuneID has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did ImmuneID last raise money?
ImmuneID's most recent round on record is a Series A, in Apr 2021.
What does ImmuneID do?
Founded in 2020 and based in Massachusetts, US, ImmuneID, Inc.
Where is ImmuneID headquartered?
ImmuneID is headquartered in Cambridge, US.
Which VCs invest in companies like ImmuneID?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at ImmuneID's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like ImmuneID? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.